Important research on many innovative pharmaceutical companies on the Science and Technology Innovation Board was selected as oral reports of top international conferences

Important research on many innovative pharmaceutical companies on the Science and Technology Innovation Board was selected as oral reports of top international conferences

Recently, many innovative pharmaceutical companies listed on the Science and Technology Innovation Board have demonstrated breakthrough research results at top global academic conferences, which has attracted widespread attention from the industry. These studies not only represent the highest level in the domestic biomedicine field, but also demonstrate the competitiveness of science and technology innovation board companies on the international stage. The following is a review of the hot topics in the past 10 days:

1. Overview of core data

2. Analysis of research highlights

1.Junshi BioPhase III clinical data on PD-1 tripleprizumab combined with chemotherapy for esophageal squamous cell carcinoma, which was released at the ASCO annual meeting, showed that the median progression-free survival (PFS) reached 6.4 months, which was significantly better than the 3.7 months in the chemotherapy group (HR=0.52).

2.InnobiThe latest data on BCMA CAR-T therapy released by the European Hematology Association Annual Meeting (EHA) showed an objective response rate (ORR) of 83% in patients with relapsed/refractory multiple myeloma, of which the complete response (CR) rate reached 42%.

3.BeiGeneThe final analysis results of the ALPINE study published in zebutinib head-to-head vs ivitinib confirmed the efficacy in the treatment of chronic lymphocytic leukemia (CLL), with the 24-month PFS rate of 78.4% vs 65.9%, respectively.

4.Rongchang BioPhase II clinical data of vedicitumab in urothelial carcinoma showed that the confirmed objective response rate (cORR) reached 50.6%, of which the ORR of patients with high HER2 expression was as high as 62.5%.

III. Industry impact analysis

The concentrated appearance of these research results reflects the three major development trends of innovative pharmaceutical companies on the Science and Technology Innovation Board:

1.Improved R&D efficiency: The average cycle from target discovery to clinical verification has been shortened to 4-5 years, which is about 30% faster than traditional pharmaceutical companies.

2.Deepening of internationalization: All selected studies adopt international multi-center clinical trial design, covering an average of 12 countries.

3.The technology platform is mature: Establish independent intellectual property platforms in cutting-edge fields such as dual antibody, ADC, and cell therapy, with the average annual growth of relevant patents by 45%.

4. Capital market reaction

5. Expert opinion

Li Ming, chief analyst of the pharmaceutical industry, pointed out: "The performance of this group of pharmaceutical companies on the Science and Technology Innovation Board has broken three traditional perceptions: First, China's innovative drugs are no longer just fast-follow, and first-in-class projects have begun to appear; second, the quality of clinical research has reached the international first-class level; third, the commercialization capacity has been significantly improved, and on average, each product has 3.2 overseas authorized cooperation."

It is worth noting that these companies remain high in R&D investment intensity, with the average R&D expense rate in 2022 reaching 58.7%, significantly higher than the level of 15-20% of large international pharmaceutical companies. This high-intensity investment is transforming into substantial innovative output. According to statistics, the four companies have accumulated 17 new IND applications this year, involving multiple major diseases such as tumors, autoimmunity, and metabolism.

With the continuous disclosure of more clinical data, it is expected that the innovative drug sector of the Science and Technology Innovation Board will usher in a revaluation of value. Institutions predict that by 2025, the proportion of overseas revenue of these leading companies is expected to increase from the current average of 12% to more than 35%, truly achieving a leap from "China's new" to "global new".